Usana Health Sciences, Inc., a Utah-based nutritional, skincare and dietary products manufacturer, indicates in its recently filed 8-K that it has substantially completed an internal investigation into whether the expense reimbursement policy and other practices at its Chinese affiliate, BabyCare Ltd., were compliant with the Foreign Corrupt Practices Act. The company reports that it is cooperating with the DOJ and the SEC in their investigations of the matter.
February 5, 2019
DOJ and SEC investigating nutritional supplement maker for possible FCPA violations
Related by Topic
VEON settles class action lawsuit to resolve allegations stemming from 2016 FCPA resolutions
May 25, 2026
News Alert
SEC closes FCPA investigation into Methode Electronics
May 19, 2026
News Alert
Stericycle’s former finance director arrested on charges of FCPA violations
May 4, 2026
News Alert